Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
Condition: Chikungunya Virus Infection Intervention: Biological: VLA1553 Sponsor: Valneva Austria GmbH Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials